ONO-1162 Phase II Study A placebo-controlled multicenter double-blind randomized parallel-group study in patients with chronic heart failure

INTERVENTION: Intervention name : ONO‐1162 Dosage And administration of the intervention : Starting dose of ONO‐1162 is 2.5mg or 5mg twice daily and then the dosage can be adjusted based on resting heart rate and tolerance. Control intervention name : Placebo Dosage And administration of the control intervention : Matching placebo twice daily CONDITION: Chronic heart failure PRIMARY OUTCOME: Change in resting heart rate from baseline SECONDARY OUTCOME: Resting heart rate, NYHA functional classification INCLUSION CRITERIA: 1. Patients with optimal CHF treatment 2. Left ventricular ejection fraction rate is =<35%. 3. Patients in sinus rhythm and with resting heart rate >=75bmp